RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ALX Oncology Holdings Stock

ALX Oncology Holdings Employees 2025

ALX Oncology Holdings Employees

23

Ticker

ALXO

ISIN

US00166B1052

WKN

A2P79Z

In 2025, ALX Oncology Holdings employed 23 people, a 0% change from the 23 number of employees in the previous year.

ALX Oncology Holdings Aktienanalyse

What does ALX Oncology Holdings do?

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining ALX Oncology Holdings's Employee Base

ALX Oncology Holdings's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding ALX Oncology Holdings's operational capacity and future potential.

Year-to-Year Comparison

Assessing ALX Oncology Holdings's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

ALX Oncology Holdings's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in ALX Oncology Holdings’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about ALX Oncology Holdings stock

How many employees does ALX Oncology Holdings have this year?

ALX Oncology Holdings has 23 undefined employees this year.

How many employees did ALX Oncology Holdings have compared to the previous year?

Compared to the previous year, ALX Oncology Holdings had 0% more employees.

What impact did the number of employees have on the company ALX Oncology Holdings?

The number of employees has a direct impact on the efficiency and productivity of ALX Oncology Holdings. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of ALX Oncology Holdings?

The number of employees can also have an impact on investors of ALX Oncology Holdings, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of ALX Oncology Holdings affect the company?

An increase in equity of ALX Oncology Holdings can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in ALX Oncology Holdings's equity affect the company?

A reduction in equity of ALX Oncology Holdings can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of ALX Oncology Holdings?

Some factors that can influence the equity of ALX Oncology Holdings include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of ALX Oncology Holdings so important for investors?

The equity of ALX Oncology Holdings is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at ALX Oncology Holdings influence the company?

The number of employees at ALX Oncology Holdings can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at ALX Oncology Holdings evolved in recent years?

In recent years, the number of employees at ALX Oncology Holdings has changed by 0.

How many employees does ALX Oncology Holdings currently have?

ALX Oncology Holdings currently has 23 undefined employees.

Why is the number of employees important for investors of ALX Oncology Holdings?

The number of employees is important for investors of ALX Oncology Holdings as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can ALX Oncology Holdings take to change the number of employees?

To change the number of employees, ALX Oncology Holdings can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 3/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of ALX Oncology Holdings in the year 2024?

In the year 2024, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.